WuXi AppTec Q2 2025 Earnings ReportFinancial statementsU.S. CDMOs face strategic setbacks amid global supply chain shifts, while China, South Korea, and Europe intensify competition in high-growth biotech sectors like CGT and ADC, reshaping the global CDMO landscape.
Basf Q2 2025 Earnings ReportFinancial statementsBASF's Q2 2025 net income plunged 81.4% amid weak demand and falling prices. The company adjusted its full-year forecast and announced key updates on its PA6.6 and Styrodur? businesses, including acquisitions and divestitures.
Takeda's 2024 Financial reportMarket TrendTakeda projects $11B in peak sales from three key drug candidates—TAK-279, TAK-861, and TAK-121—while restructuring its pipeline to drive future growth and profitability.
AkzoNobel India's Revenue and Business Sale PlansMarket TrendAkzoNobel India's revenue for FY 2025 grew to INR 40.91B, with a 3% increase. The company plans to sell its decorative paint business and undergoes strategic evaluations for long-term growth.
Nippon Paints's Q1 2025 Financial reportMarket TrendNippon Paint reports 2.6834 Billion dollars Q1 revenue in FY2025, with China retail up 5% and net profit rising 13%. Despite a slight dip in China revenue, profits surged due to cost controls and volume growth.
Asian Paints's Q1 2025 Financial reportMarket TrendDiscover the fascinating story behind the discovery of #streptomycin and its impact on #tuberculosis treatment. Explore the clash between mentor and student, #Waksman and #Schatz, and the legacy of this groundbreaking antibiotic.
Dr. Reddy's Q1 2025 Financial reportMarket TrendDr. Reddy's FY2024 revenue rose 17% to $3.81B, driven by strong generics, strategic acquisitions, and a focus on OTC and healthcare. Net profit grew 2.8% as the company expanded globally.
Takeda's 2024 Q4 Financial reportMarket TrendTakeda's 2024 fiscal report shows 7.4% revenue growth to ￥4.58T, driven by strong core business and R&D breakthroughs. Key segments include GI, rare diseases, oncology. Outlook for 2025 remains stable despite VYVANSE competition.
Axalta's Q1 2025 Financial reportMarket TrendAxalta reported Q1 2025 revenue of $1.262 billion, down 2.5% YoY, with strong 17% growth in China driven by surging auto production. Net income rose 154% to $99M amid cost improvements.
